FDA regulatory roundup: approvals, rejections & 1 clinical hold

The latest stories trending on MedCity News.

Not rendering correctly? View this email as a web page here. TOP STORIES FDA regulatory roundup: two approvals, three rejections & one clinical hold The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and Reata Pharmaceuticals. SPONSORED Diversity through accessibility: How in-home clinical trials can enroll more patients of color From Workpath & MedCity News Clinical trials have long struggled to enroll participants that reflect the demographics of a patient population, but new models can change that. Digital health intelligence company MDisrupt lands $5.7M seed funding By Emma Bardin Monday, March 7, 2022 7:00 AM MDiscrupt will utilize the seed funding to develop its digital health intelligence platform, build out its product and engineering teams in Austin, and grow its commercial teams. Read more » Developing trustworthy AI solutions for healthcare By Anthony Vetro Sunday, March 6, 2022 12:00 PM Artificial intelligence could help with improving patient care, accelerating drug discovery and enabling the efficient operation and management of healthcare systems. But the focus should be on AI that can assist with human decision-making, not replace it. Read more » RubiconMD CEO shares insights on behavioral health and outlines rural health initiative [Sponsored] By Stephanie Baum Sunday, March 6, 2022 11:05 AM Gil Addo, CEO and co-founder of RubiconMD, is taking part in a discussion on value-based care and access to healthcare in rural communities at the ViVE conference by HLTH and CHIME in Miami Beach March 6-9. In an interview, he discussed behavioral health and rural health initiatives. Read more » FDA regulatory roundup: two approvals, three rejections & one clinical hold By Frank Vinluan Sunday, March 6, 2022 10:55 AM The FDA approved drugs from Johnson & Johnson and CTI BioPharma in the past week. Complete response letters were issued to Gilead Sciences, Amryt, and Reata Pharmaceuticals. Read more » Ambulatory surgery centers, transparency, and industry flexibility: The road to improving U.S. healthcare By Itai Nemovicher Sunday, March 6, 2022 10:00 AM With their ability to provide cost-effective care and statistically safer clinical outcomes than in-patient facilities, ambulatory surgery centers are a key to moving affordable healthcare forward. Read more » Revised CDC guidelines on opioids are a step in the right direction, but much work remains By Bob Azelby Sunday, March 6, 2022 9:00 AM More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options. Read more » MedCity INVEST 2022   MedCity INVEST 2022 at The Ritz Carlton Chicago is a 3 day gathering with numerous opportunities for in-person networking and learning around the latest technologies and investment trends from VCs and successful entrepreneurs.   Register Now MedCity News   611 Broadway    New York,  NY   10012   United States You received this email because you are subscribed to MedCity Daily Digest from MedCity News. Update your email preferences to choose the types of emails you receive.  Unsubscribe from all future emails